Press room

20th December 2018
DMXD-011  is an orally-bioavailable and selective inhibitor of TBK1 and IKK-epsilon, invented by Domainex, that is presently in pre-clinical development.
20th December 2018
The results of a productive collaboration between Domainex and Oxford University have been published in a recent Nature Communications paper titled "Small molecule inhibitors of RAS-effector protein interactions derived using an intrace
20th September 2018
Cambridge, UK, 20th September 2018 / Domainex Ltd, a privately-owned drug research services company, is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018.
30th April 2018
Cambridge, UK, 30th April 2018 / Domainex Ltd, a privately-owned drug discovery services company, is proud to announce its inclusion in the second annual top 1000 list of Europe’s fastest growing companies, published by the Financial Times.  Th
12th September 2017
Cambridge, UK and Stevenage, UK – 12 September 2017 - Domainex and Auspherix have announced new data from their collaboration to develop novel candidate drugs to tackle the growing thr
17th May 2017
Domainex signs multi-year agreement with Dotmatics – a leading provider of scientific informatics – to streamline its integrated drug discovery services
7th March 2017
Domainex launched its fragment screening service, FragmentBuilder, and is the first CRO in the UK to offer MicroScale Thermophoresis (MST) as part of drug discovery services.
15th December 2016
Domainex has purchased a Monolith NT. Automated instrument, using MicroScale Thermophoresis (MST) technology for high-throughput fragment-based drug discovery.